Login / Signup

Prediction of Drug-Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation.

Zhe WangXiaoyu WangZhen WangXiaoyu FanMingrui YanLili JiangYangliu XiaJun CaoYong Liu
Published in: European journal of drug metabolism and pharmacokinetics (2022)
Dabrafenib is a potent noncompetitive inhibitor of UGT1A1 and may bring potential risk of DDI when combined with irinotecan.
Keyphrases
  • adverse drug
  • drug induced
  • emergency department
  • anti inflammatory
  • human health